Theoretical considerations for the ideal aromatase inhibitor.
- 1 May 1998
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 49 (1) , S39-S44
- https://doi.org/10.1023/a:1006088405721
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Absolute bioavailability of letrozole in healthy postmenopausal womenBiopharmaceutics & Drug Disposition, 1997
- Aromatase inhibitors: current status and future applicationsEndocrine-Related Cancer, 1997
- PP-8-3 Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA)European Journal Of Cancer, 1996
- Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancerBritish Journal of Cancer, 1996
- Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteersBritish Journal of Cancer, 1996
- The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patientsEuropean Journal Of Cancer, 1992
- The influence of CGS 16949A on peripheral aromatisation in breast cancer patientsBritish Journal of Cancer, 1991
- Clinical development of aromatase inhibitors for the treatment of breast and prostate cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- Aminoglutethimide in the treatment of advanced breast cancerCancer Treatment Reviews, 1984
- Studies on the Mechanism of Estrogen Biosynthesis. VIII. The Development of Inhibitors of the Enzyme System in Human Placenta1Endocrinology, 1973